



Relationship to other Nature Research journals	1	Post-Acceptance	5
Article Type Specifications	2	Publication Charges	6
Preparation of Articles	3	Editorial Policies	7
How to Submit	5	Further information	9

RELATIONSHIP TO OTHER NATURE RESEARCH JOURNALS

npj Vaccines is an open access, online-only, Nature Research journal published by Springer Nature in partnership with the Sealy Center for Vaccine Development at the University of Texas Medical Branch.

npj Vaccines is editorially independent. The editors make their own decisions, independently of the other Nature Research journals.

If a paper is rejected from one Nature Research journal, the authors can use an automated manuscript transfer service to submit the paper to another journal via a link sent to them by the editor handling the manuscript.

In cases where manuscripts are rejected from *npj Vaccines*, authors may wish to use the same manuscript transfer service to submit their paper to other Nature Research journals.

For more information, please consult the following:

[Details of the manuscript transfer service](#)

[Listing of all Nature journals](#)

[A general explanation of the relationship between Nature Research titles](#)

ARTICLE TYPE SPECIFICATIONS

Article Description	Abstract	Word Limit	Tables/Figures	References guideline
Article A complete, comprehensive report of original research. An Article usually has a fairly complex narrative that is based on multiple techniques and/or approaches.	Unstructured abstract; max word limit: 250	5,000 words excluding abstract, references, figures and tables	Max of 6	50 . Please use as current as possible.
Brief Communication A concise report of research of high quality and broad interest to a journal's target audience. Usually a short report of interim work or final report of research that does not warrant a full research paper publication.	Unstructured abstract; max word limit: 150	800 words excluding references	Max of 2	10
Correspondence The Editors will occasionally consider the publication of correspondence developing the debate relating to a particular journal article that has already been published in the journal. These would usually be published alongside a reply from the authors of the original article. These pieces are not applicable for an Article Processing Charge.	None	800 words excluding, references, figures and tables	None	10 , not including reference to the original article.
Comment An opinionated piece that focus on a topical issue.	None	1,500 words excluding reference	Max of 2	Max of 15
Case Report The Editors welcome submission of patient-oriented evidence-based case reports. A Discussion section should highlight the educational nature of the case(s) being presented.	Unstructured abstract; max word limit: 250	2,000 words excluding abstract, references, figures and tables	Max of 2	50

Editorial An authoritative timely opinion on an issue or a paper; it is usually written or invited by the Editor-in-Chief.	None	1,000 words excluding references	Max of 2	15
Meeting Report An account of proceedings at a recent conference of broad interest to the target readership of the journal.	Unstructured abstract; max word limit: 150	Maximum of 2,000 words excluding abstract, references, figures and tables	Max of 2	50
Perspective It should provide an evidence-based opinion on a particular article or subject. There should be a short introduction, followed by relevant section headings and a conclusions' section at the end. The standard footer headings (Acknowledgements, Contributions, Competing Interests, Funding) are required.	Unstructured abstract; max word limit: 250	2,000 words excluding abstract, references, figures and tables	Max of 3	50
Protocol A report of proven protocols.	None	3,000 words excluding references	Max of 5	50
Review A comprehensive synthesis and/or analysis of specific topics. A short Introduction giving the rationale for the review should be followed by sections with appropriate subheadings, followed by a conclusions section at the end. The standard footer headings (Acknowledgements, Contributions, Competing Interests, Funding) are required. All invited reviews will undergo peer review prior to acceptance.	Unstructured abstract; max word limit: 250	5,000 words excluding abstract, references, figures and tables	Max of 8	100

Word limit

Word limits are provided for guidance only. The Editors will consider submissions that exceed the recommended limit, subject to feedback received during peer review.

PREPARATION OF ARTICLES

Please note that Articles must contain the following components in the order stated. Please see below for further details.

- Title page
- Abstract and keywords
- Introduction
- Results
- Discussion
- Methods
- Acknowledgements
- Competing Interests
- Contributions
- Funding
- References
- Figure legends
- Tables
- Figures

Cover Letter: The uploaded cover letter must state the material is original, has not been previously published in another peer-reviewed journal and has not been submitted

for publication elsewhere while under consideration. A [Competing Interests](#) statement should also be included.

Manuscript text: All textual content is provided in a single file, prepared using either Word or TeX/LaTeX; figures are provided in individual files.

Word: Nature Partner Journals do not use a manuscript template for Word documents. The manuscript file should be formatted as double spaced, single-column text without justification. Pages should be numbered using an Arabic numeral in the footer of each page. Standard fonts are recommended and the 'symbols' font should be used for representing Greek characters.

TeX/LaTeX: Authors submitting LaTeX files may use any of the standard class files such as article.cls, revtex.cls or amsart.cls. Non-standard fonts should be avoided; please use the default Computer Modern fonts. For the inclusion of graphics, we recommend graphicx.sty. Please use numerical references only for citations. There is no need to spend time visually formatting the manuscript: journal style will be imposed when the paper is prepared for publication.

References should be included within the manuscript file itself.

BibTeX bibliography files: Authors who wish to use BibTeX to prepare their references should copy the reference list from the .bbl file that BibTeX generates and paste it into the main manuscript .tex file (and delete the associated `\bibliography` and `\bibliography` style commands). As a final precaution, authors should ensure that the complete .tex file compiles successfully on their own system with no errors or warnings, before submission.

Title Page: The title page should bear the title of the paper, the full names of all the authors and their affiliations, together with the name, full postal address, telephone and e-mail address of the author to whom all correspondence is to be addressed.

- The title should be brief, informative, of 150 characters or less.
- The running title should consist of no more than 50 letters and spaces. It should be as brief as possible, convey the essential message of the paper and contain no abbreviations.
- Authors should disclose the sources of any support for the work, received in the form of grants and/or equipment and drugs.
- If authors regard it as essential to indicate that two or more co-authors are equal in contribution status, they may be identified by an asterisk symbol with the caption 'These authors contributed equally to this work' immediately under the address list.

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Abstract: Abstracts should be unstructured and of no more than 250 words.

Introduction: The Introduction should assume that the reader is knowledgeable in the field and should therefore be as brief as possible, but can include a short background description/overview where desirable.

Results: The Results section should briefly present the experimental data in text, tables or figures. Tables and figures should not be described extensively in the text. Section sub-headings can be used to aid clarity.

Discussion: The discussion should focus on the interpretation and the significance of the findings with concise objective comments that describe their relationship to other work in the area. It should not repeat information in the results section.

Methods: This section should contain sufficient detail, so that all experimental procedures can be reproduced, and include references. However, methods that have been published in detail elsewhere should not be described in detail. Authors should provide the name of the manufacturer for any specifically named equipment and instruments; if applicable, all drugs should be identified by their pharmaceutical names, and by their trade name if relevant. Section sub-headings should be used to aid clarity.

Availability of data, materials and methods: An inherent principle of publication is that others should be able to replicate and build upon the authors' published claims. A

condition of publication is that authors [are required to make materials, data, code](#), and associated protocols promptly available to readers without undue qualifications.

Submission of a manuscript to *npj Vaccines* implies that materials described in the manuscript, including all relevant raw data, will be freely available to any scientist wishing to use them for non-commercial purposes, without breaching participant confidentiality.

Data availability statements: Data availability statements provide a statement about where data supporting the results reported in a published article can be found - including, where applicable, hyperlinks to publicly archived datasets analysed or generated during the study. For all original research articles, we require the provision of data availability statements, examples and details can be seen on our [data policy](#) web page. The statement should be placed at the end of the Methods section (titled, 'Data availability'), after the code availability statement if one is present. For further guidance, please refer to the Data availability and data citations [policy information](#) and [Frequently Asked Questions \(FAQs\)](#).

npj Vaccines strongly encourages that all datasets on which the conclusions of the paper rely should be available to readers. We encourage authors to ensure that their datasets are either deposited in publicly available repositories (where available and appropriate) or presented in the main manuscript or additional supporting files whenever possible. Please see Springer Nature's [information on recommended repositories](#). General repositories - for all types of research data - such as [figshare](#) and [Dryad](#) may be used where appropriate.

Where a widely established research community expectation for data archiving in public repositories exists, submission to a community-endorsed, public repository is [mandatory](#). Persistent identifiers (such as DOIs and accession numbers) for relevant datasets must be provided in the paper.

Acknowledgements: These should be brief and should include sources of support including sponsorship (e.g., university, charity, commercial organisation) and sources of material (e.g., novel drugs) not available commercially.

Contributions: The exact role(s) of each author should be included in the declaration. For research manuscripts, one or more of the authors should be identified as the guarantor. Only those who have made substantial contributions to the study and/or preparation of the manuscript should be acknowledged as authors and named in full.

Competing Interests: Authors must declare whether or not there are any competing interests in relation to the work described. This information must be included at this stage and will be published as part of the paper. Conflict of interest should be noted in the cover letter and in the paper. Please see the Conflict of Interest documentation in the [Editorial Policy](#) section for detailed information.

Funding: Authors should declare the source of funding for their research, if applicable.

References: All necessary references should be included in order to credit previous work directly relevant to the article. References should follow the *Nature* style available in most reference management software. In the text they should appear as superscript numbers starting at 1 and at the end of the paper they should be listed (double-spaced) in numerical order corresponding to the order of citation in the text. Where a reference is to appear next to a number in the text, for example, following an equation, chemical formula or biological acronym, citations should be written as (ref. X) and not as superscript. Example: “detectable levels of endogenous Bcl-2 (ref. 3), as confirmed by western blot.”

All authors should be listed for papers with up to five authors; for papers with more than five authors, the first only should be listed, followed by *et al.* Abbreviations for titles of medical periodicals should conform to those used in the latest edition of Index Medicus. The first and last page numbers for each reference should be provided. Abstracts must be identified as such. Papers in press and preprints hosted on a recognized server may be included in the list of references.

Personal communications must be allocated a number and included in the list of references in the usual way or simply referred to in the text; the authors may choose which method to use. In either case authors must obtain permission from the individual concerned to quote his/her unpublished work.

Examples:

Journal article, up to five authors:

Belkaid, Y. & Rouse, B. T. Natural regulatory T cells in infectious disease. *Nat. Immunol.* **6**, 353–360 (2005).

Journal article, e-pub ahead of print:

Bonin, M. *et al.* F-ara-A pharmacokinetics during reduced-intensity conditioning therapy with fludarabine and busulfan. *Bone Marrow Transplant.* <http://dx.doi.org/10.1038/sj.bmt.1705565> (2007).

Journal article, in press:

Gallardo, R. L., Juneja, H. S. & Gardner, F. H. Normal human marrow stromal cells induce clonal growth of human malignant T-lymphoblasts. *Int. J. Cell Cloning* (in the press).

Complete book:

Atkinson, K. *et al.* (eds) *Clinical Bone Marrow and Blood Stem Cell Transplantation* (Cambridge Univ. Press, 2004).

Chapter in book:

Harley, N. H. & Vivian, L. in *Mechanisms of Disease* 4th edn, Vol. 2 (eds Sodeman, W. A. & Smith, A.) Ch. 3 (Saunders, 1974).

Abstract:

Feig, S. A. *et al.* Bone marrow transplantation for neuroblastoma. *Exp. Hematol.* **13**, abstr. 102 (1985).

Preprint:

Starrfelt, J. & Liow, L.H. How many dinosaur species were there? Fossil bias and true richness estimated using a Poisson sampling model (TRiPS). Preprint at <http://biorxiv.org/content/early/2015/12/04/025940> (2015).

Research dataset:

Hao, Z., AghaKouchak, A., Nakhjiri, N. & Farahmand, A. Global Integrated Drought Monitoring and Prediction System (GIDMaPS) Data sets. [figshare. http://dx.doi.org/10.6084/m9.figshare.853801](http://dx.doi.org/10.6084/m9.figshare.853801) (2014).

Figure Legends: These should be brief, specific and appear on a separate manuscript page after the References section.

Tables: These should be labelled sequentially and cited within the text. Each table should be presented on its own page, numbered and titled. Reference to table footnotes should be made by means of Arabic numerals. Tables should not duplicate the content of the text. They should consist of at least two columns; columns should always have headings. Authors should ensure that the data in the tables are consistent with those cited in the relevant places in the text, totals add up correctly, and percentages have been calculated correctly. Tables should only be used to present essential data. Each must be on a separate sheet with a title or caption and be clearly labelled, sequentially. Please make sure each table is cited within the text and in the correct order, e.g. (Table 3). Tables should ideally be presented in Excel, one table per workbook. It is imperative that the tables are editable. Please save the files with extensions .xls / .xlsx / .ods / .doc or .docx. Please ensure that you provide a 'flat' file, with single values in each cell with no macros or links to other workbooks or worksheets and no calculations or functions.

Figures: Figures and images should be labelled sequentially and cited in the text. Figures should not be embedded within the text but rather uploaded as separate files. Detailed guidelines for submitting artwork can be found by downloading our [Artwork Guidelines](#). The use of three-dimensional histograms is strongly discouraged when the addition of the third dimension gives no extra information.

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information: Supplementary information (SI) is peer-reviewed material directly relevant to the conclusion of an article that is not included within the main body of the article. The article must be complete and self-explanatory without the SI, which is posted on the journal's website and linked to the article. SI may consist of data files, graphics, movies or extensive tables. Please see our [Artwork Guidelines](#) for information on accepted file types.

Authors should submit SI files in the FINAL format as they are not edited, typeset or changed, and will appear online exactly as submitted. When submitting SI, authors are required to:

- Include a text summary (no more than 50 words) to describe the contents of each file.
- Identify the types of files (file formats) submitted.
- Include the text “Supplementary information is available at (journal name)’s website” at the end of the article and before the references.

Reporting Tools: Please also ensure that, where relevant, the appropriate reporting guidance checklist (e.g. CONSORT for randomised controlled trials, PRISMA for systematic reviews, and STROBE for cohort, case-control and cross-sectional studies) has been completed and

submitted as a supplementary file. These can be obtained from <http://www.equator-network.org>.

In order to improve the overall transparency of reporting and the reproducibility of published results we require that you complete and submit the following reporting checklist http://www.nature.com/authors/policies/checklist_AJ.pdf.

House Style

- All pages and lines are to be numbered. To add page numbers in MS Word, go to Insert then Page Numbers. To add line numbers go to File, Page Setup, then click the Layout tab. In the Apply to box, select Whole document, click Line Numbers then select the Add line numbering check box, followed by Continuous.
- Use a coarse hatching pattern rather than shading for tints in graphs.
- Colour should be distinct when being used as an identifying tool.
- Units: Use metric units (SI units) as fully as possible. Preferably give measurements of energy in kilojoules or MegaJoules with kilocalories in parentheses (1 kcal = 4.186kJ). Use % throughout.

Abbreviations: On first using an abbreviation place it in parentheses after the full item. Very common abbreviations such as **FFA**, **RNA**, need not be defined. Note these abbreviations: gram **g**; litre **l**; milligram **mg**; kilogram **kg**; kilojoule **kJ**;

megajoule **MJ**; weight **wt**; seconds **s**; minutes **min**; hours **h**. Do not add s for plural units.

Language Editing: *npj Vaccines* is read by scientists from diverse backgrounds. In addition, many are not native English speakers. Authors should therefore give careful thought to how their findings may be communicated clearly. Although a shared basic knowledge of biology may be assumed, please bear in mind that the language and concepts that are standard in one subfield may be unfamiliar to non-specialists. Thus, technical jargon should be avoided as far as possible and clearly explained where its use is unavoidable. Abbreviations, particularly those that are not standard, should also be kept to a minimum. The background, rationale and main conclusions of the study should be clearly explained. Titles and abstracts in particular should be written in language that will be readily intelligible to any scientist.

Even though no paper will be rejected for poor language, non-native English speakers occasionally receive feedback from editors and reviewers regarding language and grammar usage in their manuscripts. You may wish to consider asking a colleague whose native language is English to read your manuscript and/or to use a professional editing service such as those provided by our affiliates [Nature Research Editing Service](#) or [American Journal Experts](#). Please note that the use of a language editing service is not a requirement for publication in *npj Vaccines*.

HOW TO SUBMIT

Pre-submission Enquiries

Please submit via our [online manuscript submission system](#).

Online Submission

We only accept manuscript submission via our [online manuscript submission system](#). Before submitting a manuscript, authors are encouraged to consult both our Editorial Policies and the submission instructions for our online manuscript submission system. If you have not already done so, please [register for an account](#) with our online manuscript system. You will be able to monitor the status of your manuscript online throughout the editorial process.

Submission of Revisions

Authors submitting a revised manuscript after review are asked to include the following:

- (1) A rebuttal letter, indicating point-by-point how you have addressed the comments raised by the reviewers. If you disagree with any of the points raised, please provide adequate justification in your letter.
- (2) A marked-up version of the manuscript that highlights changes made in response to the reviewers' comments in order to aid the Editors and reviewers. Do not use track changes or comments.
- (3) A 'clean' (non-highlighted) version of the revised manuscript.

POST-ACCEPTANCE

Once a manuscript is accepted, the corresponding author must complete and sign a Creative Commons licence and Article Processing Charge Payment form on behalf of all authors and return it to the editorial office. Failure to promptly return the form will result in delay of publication.

Publication

Publishing Open Access will mean the paper is freely accessible online immediately upon publication. By paying this charge authors are permitted to post the final, published PDF of their article on a website, institutional

repository or other free public server, immediately on publication.

Open access articles are published under a [CC BY](#) licence (Creative Commons Attribution 4.0 International Licence). The CC BY licence is preferred by many research funding bodies. It allows for maximum dissemination and re-use of open access materials: users are free to share (copy, distribute and transmit) and remix (adapt) the contribution including for commercial purposes, providing they attribute the contribution in the manner specified by the author or licensor ([read the full legal code](#)).

Under Creative Commons licences, authors retain copyright in their work. Authors should note that some funders require papers to be published under a specific licence and so should check the funder mandate to ensure compliance.

Open Access Waiver

Please note that some institutions have enacted Open Access policies that conflict with our own. If any corresponding or contributing authors are from these institutions, you will need to provide a waiver from the institution of every affected author, which can be obtained from the institution. This waiver should be submitted at the same time as the Open Access Licence to Publish form.

Proofs

The corresponding author will receive an e-mail containing a URL linking to the proofing site. Proof corrections must be returned within 48 hours of receipt. Failure to do so may result in delayed publication. Extensive changes cannot be made at this stage.

Final Publication

The final version of the manuscript is published online and represents the official version of the manuscript.

Self-Archiving

Authors are encouraged to submit the final version of the accepted, peer-reviewed manuscript to their funding body's archive for public release immediately upon publication and to deposit the final version on their institution's repository. Authors should cite the publication reference and DOI number on any deposited version, and provide a link from it to the published article on the Nature Research website.

This policy complements the policies of the US National Institutes of Health, the Wellcome Trust and other research funding bodies around the world. Springer Nature recognises the efforts of funding bodies to increase access of the research they fund, and strongly encourages authors to participate in such efforts.

PUBLICATION CHARGES

Article Processing Charge

Authors whose papers are accepted for publication in *npj Vaccines* are required to pay an Article Processing Charge (APC).

The following charges will apply for all un-solicited articles published in *npj Vaccines* (plus VAT where applicable):

	The Americas, China and Japan	UK	Europe and rest of world
Original Article	\$3,300	£2,170	€2,570
Other article types	\$1,530	£1,010	€1,190

Upon acceptance of their manuscript it is mandatory for authors of articles and reports to complete the APC form and licence to publish form, via our online portals. Links to the online portal will be provided upon acceptance of the article. Processing of an accepted manuscript can only proceed once these forms have completed.

Please note in regards to payment that usual credit terms are 30 days from receipt of invoice. Failure to pay your invoice within the stated credit term may result in such penalties as restrictions on your ability to publish with Springer Nature or in the Journal in the future, involvement of a third-party debt collection agency and legal proceedings.

Article Processing Charge Waiver policy

npj Vaccines offers [APC waivers](#) for papers whose corresponding authors are based in the world's lowest income countries as defined by the World Bank. Discretionary APC waivers for authors will be considered on a case-by-case basis, and may be granted in cases of financial need. All applications for discretionary APC waivers should be made prior to, or at the point of, manuscript submission. To request a waiver please contact

us at apcwaivers@springernature.com. Full details of our APC waiver and discount policies can be found [here](#).

All decisions to publish are based entirely on editorial criteria and the editors and reviewers will not have access to the information on the author's ability to pay the Article Processing Charge. Springer Nature is a partner of AGORA, HINARI, INASP - you can find more information here: <http://www.nature.com/info/partners.html>.

Open access funding

Visit Nature Research's [open access funding](#) page for information about research funders and institutions that provide funding for open access.

Nature Research also offers an APC support service to make it easier for Nature Research authors to discover and apply for open access funding. For advice on what funding is available to you and help in approaching funders and institutions, please contact us at openaccess@nature.com.

For more information about Nature Research's open access publishing options and policies, please see our [open access homepage](#).

EDITORIAL POLICIES

General publishing policies

Please see the authors & referees page for detailed information about author and referee services and publication policies of the Nature Research family of journals. These journals, including *npj Vaccines*, share a number of common policies including the following:

[Author responsibilities](#)

[Licence agreement and author copyright](#)

[Embargo policy and press releases](#)

[Use of experimental animals and human subjects](#)

[Competing Interests](#)

[Availability of materials and data](#)

[Digital image integrity and standards](#)

[Biosecurity concerns](#)

[Refutations, complaints and corrections](#)

[Duplicate publication](#)

[Confidentiality and pre-publicity](#)

[Plagiarism and fabrication](#)

Permissions

If a table or figure has been published before, the authors must obtain written permission to reproduce the material in electronic format from the copyright owner and submit it with the manuscript. This follows for illustrations and other materials taken from previously published works not in the public domain. The original source should be cited in the figure caption or table footnote. Permission to reproduce material can usually be obtained through the [Copyright Clearance Center](#).

Clinical Trials

As defined by the International Committee of Medical Journal Editors (ICMJE), a clinical trial is any research project that prospectively assigns human subjects to intervention and comparison groups to study the cause-and-effect relationship between a medical intervention and a health outcome. A medical intervention is any intervention used to modify a health outcome and includes but is not limited to drugs, surgical procedures, devices, behavioural treatments, and process-of-care changes. A trial must have at least one prospectively assigned concurrent control or comparison group in order to trigger the requirement for registration. Nonrandomised trials are not exempt from the registration requirement if they meet the above criteria.

When reporting experiments on human subjects, please indicate whether the procedures were in accordance with the ethical standards of the responsible committee on human experimentation (institutional or regional) or with the Helsinki Declaration of 1975 (as revised in 1983). Include Institutional Review Board or Animal Care and Use Committee approvals.

All clinical trials must be registered in a public registry prior to submission. The journal follows the trials registration policy of the ICMJE (www.icmje.org) and considers only trials that have been appropriately registered before submission, regardless of when the trial closed to enrolment. Acceptable registries must meet the following ICMJE requirements:

- be publicly available, searchable, and open to all prospective registrants
- have a validation mechanism for registration data
- be managed by a not-for-profit organization

The trial registry number for eligible papers will be collected during the submission process.

Toolkits

Nature Research endorses the toolkits and guidelines produced by the following bodies:

[Committee on Publication Ethics](#)

[Good Publication Practice](#)

[Medical Publishing Insights and Practices Initiative](#)

Competing Interests

Authors must disclose competing interests during the submission process. Authors submitting their manuscripts using the journal's online manuscript tracking system are required to make their declaration as part of this process and to specify the competing interests in cases where they exist. More details about the Competing Interests policy can be found here:

<http://www.nature.com/authors/policies/competing.html>

Pre- and Post-Submissions

Authors are welcome to post pre-submission versions or the original submitted version of the manuscript on a personal blog, a collaborative wiki or a recognized preprint server (such as [ArXiv](#) and [bioRxiv](#)) at any time.

For content published under a Creative Commons licence, authors can replace the submitted version with the final published version at publication as long as a publication reference and URL to the published version on the journal website are provided.

Peer Review

The journal operates single blind peer review. Manuscripts sent out for peer review are evaluated by at least one independent reviewer (often two or more). Authors are welcome to suggest independent reviewers to evaluate their manuscript, as well as request individuals or laboratories. All recommendations are considered, but the choice of reviewers is at the editors' discretion. To expedite the review process, only papers that seem most likely to meet editorial criteria are sent for external review. Papers judged by the editors to be of insufficient general interest or otherwise inappropriate are rejected promptly without external review. The editors then make a decision based on the reviewers' evaluations:

- Accept, with or without editorial revisions.
- Revise, with the author addressing concerns raised by the reviewers before a final decision is reached.
- Reject, but indicate to the authors that further work might justify a resubmission.
- Reject outright, typically on grounds of specialist interest, lack of novelty, insufficient conceptual advance or major technical and/or interpretational problems.

Selecting Peer Reviewers

Reviewer selection is critical to the publication process, and the editors' choice is based on many factors, including expertise, reputation, and specific recommendations. A reviewer may decline the invitation to evaluate a manuscript where there is a perceived conflict of interest (financial or otherwise).

Appeals

Even in cases where editors did not invite resubmission, some authors ask the editors to reconsider a rejection decision. These are considered appeals, which, by policy, must take second place to the normal workload. In practice, this means that decisions on appeals often take several weeks. Only one appeal is permitted for each manuscript, and appeals can only take place after peer review.

Decisions are reversed on appeal only if the editors are convinced that the original decision was a serious mistake, not merely a borderline call that could have gone either way. Further consideration may be merited if a referee made substantial errors of fact or showed evidence of bias, but only if a reversal of that referee's opinion would have changed the original decision. Similarly, disputes on factual issues need not be resolved unless they were critical to the outcome. Thus, after careful consideration of the authors' points, most appeals are rejected by the editors.

If an appeal merits further consideration, the editors may send the authors' response or the revised paper to one or more referees, or they may ask one referee to comment on the concerns raised by another referee. On occasion, particularly if the editors feel that additional technical expertise is needed to make a decision, they may obtain advice from an additional referee.

Correction and Retraction Process

Published content is final and cannot be amended. The online version is part of the published record hence the original version must be preserved and changes to the paper should be made as a formal correction. If an error is noticed in an article, a correction should accompany the article. An HTML (or full-text) version of the correction will also be created and linked to the original article.

Please note the following categories of corrections to peer reviewed content:

- Publisher correction. Notification of an important error made by the journal that affects the publication record or the scientific integrity of the paper, or the reputation of the authors, or of the journal.
- Author correction. Notification of an important error made by the author that affects the publication record or the scientific integrity of the paper, or the reputation of the authors or the journal.
- Retraction. Notification of invalid results. All co-authors must sign a retraction specifying the error and stating briefly how the conclusions are affected.

Decisions about corrections are made by the Editor (sometimes with peer-reviewers' advice) and this sometimes involves author consultation. Requests to make corrections that do not affect the paper in a significant way or impair the reader's understanding of the contribution (a spelling mistake or grammatical error, for example) are not considered.

In cases where co-authors disagree about a correction, the editors may take advice from independent peer reviewers and impose the appropriate correction, noting the dissenting author(s) in the text of the published version.

FURTHER INFORMATION

For inquiries related to submission requirements, please contact the [editorial office](#). For inquiries related to advertising, subscriptions, permissions, papers in production or publishing a supplement, please contact the [publisher's office](#).